Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients (pts) with microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI).
Randomized trial evaluates ctDNA dynamics correlated with outcomes in MSI-H metastatic colorectal cancer, implying potential for better treatment strategies.
Key Points
This research aims to understand how ctDNA dynamics relate to treatment outcomes in patients with MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors.
Identified patients with MSI-H mCRC treated with first-line ICIs from Natera’s Real-World Database, linking ctDNA results and claims data.
Estimated overall survival using mortality data and assessed ctDNA status before and after ICI treatment.
Evaluated time to next treatment and ctDNA levels post-ICI initiation.
Among 559 patients, 71.7% were ctDNA-positive before treatment; 81.0% achieved ctDNA clearance after ICI.
ctDNA positivity at any point after ICI initiation predicted inferior OS (HR: 4.9, p < 0.001).
Those with ctDNA-negative tests post-ICI had longer treatment duration (median 303 days) compared to ctDNA-positive (median 192 days).